31 March 2022 - PHARMAC has negotiated an agreement with AstraZeneca for its pre-exposure prophylactic COVID-19 treatment, which would be targeted to our most vulnerable New Zealanders.
Tixagevimab with cilgavimab (supplied under the brand name Evusheld) is PHARMAC’s fourth advance purchase agreement for a COVID-19 treatment, and its first for a pre-exposure prophylactic treatment.